ArticleTranslational cancer research2025
SNX24 serves as a potential prognostic biomarker and a therapeutic target in uterine corpus endometrial carcinoma according to bioinformatics and experimentations.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine corpus endometrial carcinoma (UCEC) which is originated from endometrial epithelium, ranks the second among frequent malignant tumors in female reproductive system. The discovery of novel therapeutic targets is urgently needed to address unmet clinical demands. In this study, we conducted a comprehensive bioinformatic analysis to identify key drivers of UCEC. Methods: The prognostic factors for UCEC were analyzed by Human Protein Atlas (HPA), The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN), and Encyclopedia of RNA Interactomes (ENCORI). The expression levels of the overlapped prognostic factors were analyzed by UALCAN, and ENCORI. The heatmap of the potential 12 prognostic factors was exhibited by UALCAN. The online databases including BioGrid, BioPlex and OpenCell were utilized to predict the molecules which could interact with SNX24. Cell proliferation was assessed by Cell Counting Kit 8 (CCK-8) assay. Cell invasion was detected by transwell assay. Results: Of note, higher SNX24 predicted a worse prognosis of patients with UCEC, and SNX24 was overexpressed in patients with UCEC, as revealed by HPA, UALCAN and ENCORI. There were two molecules which could interact with SNX24, i.e., the casein kinase 1 (CSNK1A1 and CSNK1E). Silencing of SNX24 significantly inhibited proliferation and invasion of endometrial carcinoma (EC) cells by downregulating the expression of CSNK1A1 and CSNK1E. Conclusions: Taken together, our data demonstrated the prognostic significance and tumor-promoting role of SNX24 in UCEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.